Answers are grounded in this paper and cite their sources.
Immune thrombocytopenia (ITP) is an acquired hematologic disorder marked by immune-mediated destruction of platelets, leading to profound thrombocytopenia and increased bleeding risk. Drug-induced immune thrombocytopenia (DITP), specifically vancomycin-induced immune thrombocytopenia (VIIT), is a rare but serious adverse drug reaction, caused by drug-dependent antibodies that accelerate platelet clearance. We present a case of a 72-year-old male who developed life-threatening thrombocytopenia, with a nadir of <1 K/µL, following re-exposure to vancomycin. The decline began within three days of treatment reinitiation and persisted despite platelet transfusions, corticosteroids, and intravenous immunoglobulin (IVIG). A diagnosis of VIIT was made after excluding other etiologies, including heparin-induced thrombocytopenia (HIT), thrombotic microangiopathy, and sepsis-associated thrombocytopenia. Platelet counts remained refractory until plasmapheresis and drug discontinuation, with recovery to 71 K/µL within one week. This case highlights the importance of early recognition of VIIT and suggests a potential role for plasmapheresis in refractory cases. Prompt drug discontinuation is critical for recovery.
No takes yet. Share an insight, caveat, or question.
Gakhar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: